Table 2.

Analysis of prognostic factors for patients with metastatic renal clear cell carcinoma receiving cytoreductive nephrectomy

Factors	Median survival time (months)	Univariate analysis		Multivariate analysis
		HR (95% CI)	P	HR (95% CI)	P
Gender		1.453 (0.769–2.745)	0.246	0.945 (0.373–2.397)	0.906
Male	39.4
Female	23.2
Age		2.291 (1.266–4.145)	0.007	4.151 (1.681–10.251)	0.002
>45 years	40.0
≤45 years	19.8
BMI		3.362 (1.827–6.187)	0.000	4.247 (1.462–12.334)	0.008
19–30 kg/m2	39.4
<19 or >30 kg/m2	9.0
LDH		2.865 (1.593–5.152)	0.001	2.832 (1.313–6.110)	0.025
≤1.5 × UNL	40.0
>1.5 × UNL	14.5
Anemia		3.001 (1.574–5.724)	0.003	2.593 (0.968–6.946)	0.058
No	40.0
Yes	15.7
Blood calcium		1.998 (1.045–3.823)	0.004	2.637 (1.076–6.462)	0.034
≤10 mg/ml	39.4
>10 mg/ml	18.0
T stage		0.866 (0.593–1.264)	0.746	0.962 (0.526–1.758)	0.899
T1	32.2
T2	34.0
T3	7.6
T4	23.0
Number of metastatic sites		2.913 (1.621–5.234)	0.047	2.554 (1.135–5.747)	0.023
1–2	40.0
≥3	23.2
Pulmonary metastasis		0.829 (0.387–1.777)	0.572	2.451 (0.728–8.246)	0.148
No	41.0
Yes	30.4
Drugs		1.097 (0.866–1.389)	0.969	1.265 (0.848–1.887)	0.250
Sunitinib	34.0
Pazopanib	39.4
Sorafenib	26.7
Famitinib	23.2

BMI: Body mass index; LDH: Lactate dehydrogenase; UNL: Upper limit of normal; HR: Hazard ratio; CI: Confidence interval.